Holen Sie sich die Stockscreener-App
20.34
3.35%
0.66
Schlusskurs vom Vortag:
$19.68
Offen:
$19.76
24-Stunden-Volumen:
1.14M
Relative Volume:
0.85
Marktkapitalisierung:
$2.49B
Einnahmen:
$460.48M
Nettoeinkommen (Verlust:
$142.80M
KGV:
17.24
EPS:
1.18
Netto-Cashflow:
$221.79M
1W Leistung:
-8.46%
1M Leistung:
-6.74%
6M Leistung:
-10.40%
1J Leistung:
+5.39%
1-Tages-Spanne:
$19.57
$20.36
1-Wochen-Bereich:
$19.15
$22.53
52-Wochen-Spanne:
$19.00
$26.58
Catalyst Pharmaceuticals Inc Stock (CPRX) Company Profile
Firmenname
Catalyst Pharmaceuticals Inc
Sektor
Branche
Telefon
(305) 529-2522
Adresse
355 ALHAMBRA CIRCLE, CORAL GABLES
Vergleichen Sie CPRX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CPRX
Catalyst Pharmaceuticals Inc
|
20.34 | 2.41B | 460.48M | 142.80M | 221.79M | 1.18 |
|
VRTX
Vertex Pharmaceuticals Inc
|
387.77 | 96.01B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
556.55 | 57.86B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
429.93 | 57.02B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
637.56 | 39.10B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.10 | 34.45B | 3.81B | -644.79M | -669.77M | -6.24 |
Catalyst Pharmaceuticals Inc Stock (CPRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-04 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-11-18 | Eingeleitet | Stephens | Overweight |
| 2024-03-14 | Eingeleitet | Citigroup | Buy |
| 2024-03-07 | Eingeleitet | BofA Securities | Buy |
| 2023-12-21 | Eingeleitet | Oppenheimer | Outperform |
| 2022-08-24 | Herabstufung | ROTH Capital | Buy → Neutral |
| 2018-09-21 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-09-07 | Fortgesetzt | Piper Jaffray | Overweight |
| 2016-10-05 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2016-04-26 | Herabstufung | Piper Jaffray | Overweight → Neutral |
| 2014-09-30 | Bestätigt | ROTH Capital | Buy |
| 2014-09-16 | Bestätigt | ROTH Capital | Buy |
| 2014-09-15 | Bestätigt | H.C. Wainwright | Buy |
| 2013-10-21 | Bestätigt | Aegis Capital | Buy |
| 2013-09-24 | Eingeleitet | Maxim Group | Buy |
| 2013-09-06 | Bestätigt | Aegis Capital | Buy |
| 2013-04-18 | Eingeleitet | Aegis Capital | Buy |
| 2012-08-27 | Hochstufung | Rodman & Renshaw | Mkt Perform → Mkt Outperform |
| 2009-10-01 | Hochstufung | Merriman | Sell → Neutral |
| 2009-05-29 | Herabstufung | Hapoalim | Neutral → Underperform |
| 2009-05-29 | Herabstufung | Merriman Curhan Ford | Buy → Sell |
| 2008-12-15 | Eingeleitet | Merriman Curhan Ford | Buy |
| 2007-11-28 | Eingeleitet | Rodman & Renshaw | Mkt Outperform |
| 2007-01-31 | Eingeleitet | Stifel Nicolaus | Buy |
| 2007-01-05 | Eingeleitet | First Albany | Buy |
Alle ansehen
Catalyst Pharmaceuticals Inc Aktie (CPRX) Neueste Nachrichten
Catalyst Pharmaceuticals: A Developing Story That's Cheap Enough (NASDAQ:CPRX) - Seeking Alpha
Catalyst Pharmaceuticals Reports Strong Q2 2025 Earnings - TipRanks
Catalyst Pharmaceuticals reaffirms $545M-$565M 2025 revenue guidance while accelerating FIRDAPSE oncology expansion - MSN
Catalyst Pharma Receives Buy Rating and Price Target of $34.00 from Bank of America Securities Analyst Jason Gerberry. - AInvest
Catalyst Pharmaceuticals Q2 Earnings Beat, Firdapse Revenues Rise Y/Y - MSN
Oppenheimer Maintains Catalyst Pharmaceuticals(CPRX.US) With Buy Rating, Maintains Target Price $32 - 富途牛牛
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Q2 2025 Earnings Call Transcript - Insider Monkey
Catalyst Pharma Reports Record Q2 2025 Financial Results - The Globe and Mail
Catalyst Pharma Updates Guidelines for SCLC Treatment - TipRanks
Transcript : Catalyst Pharmaceuticals, Inc., Q2 2025 Earnings Call, Aug 07, 2025 - MarketScreener
Earnings call transcript: Catalyst Pharmaceuticals Q2 2025 beats EPS forecast - Investing.com
Rigel Pharmaceuticals, Inc. (RIGL) Hits Fresh High: Is There Still Room to Run? - Yahoo Finance
Catalyst Pharmaceuticals (NASDAQ:CPRX) Stock Performs Better Than Its Underlying Earnings Growth Over Last Five Years - 富途牛牛
Catalyst Pharmaceutical Partners Inc. Exceeds Q2 Earnings ExpectationsNews and Statistics - IndexBox
Catalyst Pharmaceuticals shares rise 1.70% premarket after Q2 revenue and adjusted EPS beat expectations. - AInvest
Catalyst Pharmaceuticals Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Catalyst Pharmaceuticals reports Q2 EPS 68c, consensus 54c - TipRanks
Catalyst Pharmaceutical (CPRX) Q2 Earnings and Revenues Surpass Estimates - Yahoo Finance
Catalyst Pharmaceuticals earnings beat by $0.29, revenue topped estimates - Investing.com Canada
Catalyst Pharmaceuticals Q2 revenue, adjusted EPS beats expectations, reaffirms 2025 revenue guidance - MarketScreener
Catalyst Pharmaceuticals Reports Record Second Quarter and - GlobeNewswire
Catalyst Pharmaceuticals Reports Record Second Quarter and First Half 2025 Financial Results; Provides Business Update - Yahoo Finance
Catalyst Pharmaceuticals Announces Inclusion of VGCC Antibody Testing and Amifampridine in NCCN Guidelines for Small Cell Lung Cancer-Associated LEMS - Quiver Quantitative
Lambert Eaton Myasthenic Syndrome (LEMS) Antibody Testing - GlobeNewswire
90% of SCLC Patients Miss LEMS Diagnosis: NCCN Updates Guidelines with Critical Testing Protocol - Stock Titan
Catalyst Pharmaceutics to Report Q2 Earnings: What's in the Cards? - MSN
Catalyst Pharmaceutics To Report Q2 Earnings: What's In The Cards? - Barchart.com
Catalyst Pharmaceuticals, Inc.'s (NASDAQ:CPRX) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong? - simplywall.st
Catalyst Pharmaceuticals Appoints Daniel Curran, MD, to its Board of Directors - GlobeNewswire
Catalyst Pharma Appoints Dr. Curran to Board - TipRanks
Catalyst Pharmaceuticals Appoints Dr. Daniel Curran to Board of Directors - Quiver Quantitative
Ex-Takeda Rare Disease Chief Joins Catalyst Pharmaceuticals Board to Drive Strategic Growth - Stock Titan
What are the technical indicators suggesting about Catalyst Pharmaceuticals Inc.Skyrocketing returns - Jammu Links News
What are analysts’ price targets for Catalyst Pharmaceuticals Inc. in the next 12 monthsMarket-leading capital gains - Jammu Links News
What makes Catalyst Pharmaceuticals Inc. stock price move sharplyGet real-time alerts on high-potential stocks - Jammu Links News
Why is Catalyst Pharmaceuticals Inc. stock attracting strong analyst attentionDiscover stocks with superior performance - Jammu Links News
How does Catalyst Pharmaceuticals Inc. compare to its industry peersRealize consistent double-digit growth - Jammu Links News
What are the latest earnings results for Catalyst Pharmaceuticals Inc.Game-changing capital returns - Jammu Links News
How strong is Catalyst Pharmaceuticals Inc. company’s balance sheetFree Daily Trading Room Entry - Jammu Links News
When is Catalyst Pharmaceuticals Inc. stock expected to show significant growthUnlock rapid growth potential in your portfolio - Jammu Links News
What catalysts could drive Catalyst Pharmaceuticals Inc. stock higher in 2025Exceptional stock performance - Jammu Links News
What is the dividend policy of Catalyst Pharmaceuticals Inc. stockOutstanding stock performance - Jammu Links News
Is Catalyst Pharmaceuticals Inc. stock overvalued or undervaluedUnrivaled growth potential - Jammu Links News
Does Catalyst Pharmaceuticals Inc. stock perform well during market downturnsStock Strategy Insights For Fast Growth - Jammu Links News
Are Investors Undervaluing Catalyst Pharmaceuticals (CPRX) Right Now? - Yahoo Finance
How many analysts rate Catalyst Pharmaceuticals Inc. as a “Buy”Free Stock Review Backed By Experts - Jammu Links News
Catalyst Pharmaceutical (CPRX) Reports Next Week: Wall Street Expects Earnings Growth - Yahoo Finance
Can Traders Expect Breakout From Catalyst Pharmaceuticals Inc. This WeekSmart Allocation Stock Pick Insights Gaining Interest - metal.it
Finanzdaten der Catalyst Pharmaceuticals Inc-Aktie (CPRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.91%
3.06%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):